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ABSTRACT
RNA interference (RNAi) mediated by small-
interfering RNAs (siRNAs) is a highly effective
gene-silencing mechanism with great potential for
gene-therapeutic applications. siRNA agents also
exert non-target-related biological effects and
toxicities, including immune-system stimulation.
Specifically, siRNA synthesized from the T7 RNA
polymerase system triggers a potent induction of
type-I interferon (IFN) in a variety of cells. Single-
stranded RNA also stimulates innate cytokine
responses in mammals. We found that pppGn
(n=2,3) associated with the 5’-end of the short-
hairpin RNA (shRNA) from the T7 RNA polymerase
system did not induce detectable amounts of IFN.
The residual amount of guanine associated with the
5’-end and hairpin structures of the transcript was
proportional to the reduction of the IFN response.
Here we describe a T7 pppGn (n=2,3) shRNA
synthesis that does not induce the IFN response,
and maintains the full efficacy of siRNA.
INTRODUCTION
RNA interference (RNAi) is a natural biological phenom-
enon mediated by small-interfering RNA (siRNA) mole-
cules that target-speciﬁc messenger RNA (mRNA) for
degradation by cellular enzymes. RNAi has become the
method of choice for studying gene function, especially
in mammalian systems. With proof-of-concept studies
already reported against a wide variety of human
pathogens, and several innovative methods available for
delivering siRNA to a range of primary cells, there is now
an even greater role for siRNA as a potential therapeutic
strategy. siRNAs induce the global upregulation of
interferon (IFN)-stimulated gene expression (1–4), as
shown by the transfection of both enzymatically and
chemically synthesized siRNAs into cells, and by siRNAs
that are produced intracellularly following the expression
of short-hairpin RNAs (shRNAs) (2–4). These studies
documented signiﬁcant non-speciﬁc changes in gene
expression as a consequence of the delivery of siRNAs.
One simple method to limit the risk of inducing an IFN
response is to use the lowest eﬀective dose of the shRNA
vector, as advocated by Bridge et al. (1). Recently, Kim
et al. (5) demonstrated that siRNAs synthesized using the
T7 RNA polymerase system trigger a potent induction
of IFN-a and IFN-b in a variety of cells. The mediator
of this response is an initiating 50-triphosphate that is
required for IFN induction. These ﬁndings led to the
development of an improved method for bacteriophage
polymerase-mediated siRNA synthesis that incorporates
two 30-adenosines to prevent base-pairing with the
initiating guanines, thereby allowing RNase T1 and calf
intestine alkaline phosphatase (CIP) to remove the
initiating 50-nucleotides (nt) and triphosphates of the
transcripts. It is now clear that triphosphates act as
triggers to induce type I IFN via the activation of retinoic
acid-inducible protein I (RIG-I) (6,7). By contrast,
Marques et al. (8) reported that blunt siRNAs are
potent activators of RIG-I-mediated type I IFN induc-
tion, whereas siRNAs containing 30-overhangs are not.
Here, we describe a new type of shRNA, pppGn(n=2)-
shRNA, synthesized by bacteriophage polymerase, which
does not induce IFN. We also describe the anti-human
immunodeﬁciency virus type 1 (HIV-1) activity of this
shRNA, which targets the well-conserved dimerization
initiation site (DIS) of HIV-1.
MATERIALS AND METHODS
RNAs
T7 shRNAs were synthesized using the AmpliScribe
T7 High Yield Transcription Kit (Epicentre, Madison,
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the in vitro transcription of RNA, T7 primer I
(50-TAATACGACTCACTATA-30) was hybridized with
T7 primer II, which contains the antisense sequence
of each transcribed RNA, the tail sequence (50-CCTATA
GTGAGTCGTATTA-30) and the loop sequence (50-TC
TCTTGAA-30). For example, to make pppGG-luc3-
shRNA, two primers were used (50-TAATACGACTC
ACTATA-30) and (50-AAGGAGCCTTCAGGATTACA
AGATCTCTTGAATCTTGTAATCCTGAAGGCTCC
CCTATAGTGAGTCGTATTA-30). After a 1-h at 378C,
for the CIP, 50U RNA (New England Biomedical,
Beverly, MA) was added to the shRNA and incubated
at 378C for 1h. Finally, the shRNAs and siRNA were
puriﬁed by polyacrylamide gel electrophoresis (PAGE).
Cellculture
HeLa CD4
+ cells were grown in RPMI 1640 medium
(Sigma Chemical Co., St Louis, MO) supplemented with
10% (v/v) heat-inactivated fetal bovine serum, 100U/ml
penicillin and 100mg/ml streptomycin.
AssaysforIFN
The amount of IFN-b secreted into the growth medium
was determined using IFN ELISA kits (PBL Biomedical
Laboratories, Piscataway, NJ). HeLa CD4
+ or RIG-I
silencing HeLa CD4
+ cells were transfected with 100nM
shRNAs or siRNA using DMRIE-C (Invitrogen,
San Diego, CA) according to the manufacturer’s protocol,
and were placed in 12-well plates. After 90min, the cells
were washed with RPMI-1640. Medium from RNA-
transfected HeLa CD4
+ cells was collected 12h later,
serially diluted and assayed for the amount of secreted
IFN according to the manufacturer’s protocol. Each assay
was performed in triplicate. Antibody neutralization
assays were carried out by diluting the medium to 3.3%
with fresh medium and mixing with 100U/ml IFN-b
neutralizing antibody (PBL Biomedical Laboratories)
for 1h.
Dual-luciferase reporter assay
HeLa CD4
+ cells in 12-well plates were co-transfected
with 0.2mg ﬁreﬂy luciferase vector, pGL3 control vector or
pNL4-3-luc, and 0.2mg pRG-TK control vector containing
Renilla luciferase (Promega Corp. Madison, WI) using
FuGENE
TM6 (Roche Diagnostics, Basel, Switzerland)
according to the manufacturer’s protocol. shRNAs were
used at a concentration of 12.5–50nM per well. Fireﬂy
and Renilla luciferase activities were measured consecu-
tively using dual-luciferase assays (Promega) 48h after
transfection.
Assayof HIV-1 replication
HIV-1 production was monitored by determining the
HIV-1 p24 antigen concentration. HeLa CD4
+ cells were
transfected with shRNAs or LacZ (control shRNA) using
DEMRI-C (Invitrogen). After 90min, the cells were
washed with serum-free RPMI-1640 and then transfected
with pNL4-3 using FuGENE
TM6 (Roche Diagnostics)
according to the manufacturer’s protocol. The culture
medium from HeLa CD4
+ cells was harvested 2days
post-transfection. p24 Gag protein production was
detected by the HIV-1 p24 chemiluminescent enzyme
immunoassay (CLEIA; Lumipulse, Fujirebio Inc., Tokyo,
Japan), according to the manufacturer’s protocol (9).
Dual-luciferase reporter assayofIRF-3 activity
HeLa CD4
+ cells were seeded at a density of 1 10
5 cells
per well into 12-well plates for 24h, and then transfected
with 0.5mg pIRF-3/Luc DNA (10) and 0.2mg phRG-TK
using FuGENE
TM6 (Roche Diagnostics) according to the
manufacturer’s protocol. After 24h, 100nM shRNA or
0.5mg/ml polyinosinic acid:polycytidylic acid (poly I:C)
was transfected using DMRIE-C (Invitrogen). Untreated
cells were used as a control. Fireﬂy and Renilla luciferase
activities were measured consecutively using dual-
luciferase assays (Promega Corp.) 12h after transfection.
MTS assay
HeLa CD4
+ cells (2 10
4 cells/ml) were seeded into
96-well microtitre plates and incubated in the presence
of various concentrations of the test compounds. The
dilutions ranged from one-fold to ﬁve-fold, and nine
concentrations were examined. All of the experiments
were performed in triplicate. After 3days culture at 378C
in a CO2 incubator, cell viability was quantiﬁed by
a colorimetric assay monitoring the ability of viable
cells to reduce 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt (MTS; Promega Corp.) to a red formazan product
(11). The absorbances were read by a microcomputer-
controlled photometer (Titertec MultiscanR; Labsystem
Oy, Helsinki, Finland) at a single wavelength (492nm).
These values were then translated into percentages
per well.
RNA interference inHeLa CD4
+ cells
HeLa CD4
+ cells were transfected with 100nM siRNAs
targeting RIG-I (sense CGAUUCCAUCACUAUCC
AUtt; antisense, AUGGAUAGUGAUGGAAUCGtt;
Sigma Aldrich Japan, Hokkaido, Japan) using DMRIE-
C (Invitrogen) according to the manufacturer’s protocol,
and were placed in 12-well plates.
Reverse-transcription polymerase chain reaction (RT-PCR)
Total cellular RNA was prepared using TRIZOL
(Invitrogen). RIG-ImRNA was detected by a RT-PCR
High–Plus kit (Toyobo, Kyoto, Japan) with the following
speciﬁc primers: RIG-I sense, 50-TCCTTTATGAGTAT
GTGGGCA-30; and RIG-I antisense, 50-TCGGGCACA
GAATATCTTTG-30. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH)-speciﬁc primers were used as a
loading control in a separate reaction. The reaction
parameters were 2min at 948C, followed by 40 cycles of
1min at 948C and 1.5min at 608C.
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pppGn(n=2)-shRNA doesnot induce IFN
To investigate the RNAi-mediated silencing of luciferase
activity, we initially synthesized six shRNAs targeting the
luciferase gene transcript using T7 RNA polymerase. The
main advantages of this technique are its simplicity and
low cost compared with chemical synthetic RNA (12,13).
The luc-shRNAs include a 50-pppGn (n=2) sequence,
because eﬃcient T7 RNA polymerase initiation requires
the ﬁrst and second non-transcribed spacer of each RNA
to be a guanine.
To determine whether pppGn(n=2)-shRNA-luc speci-
ﬁcally inhibited luciferase gene expression, HeLaCD4
+
cells were transfected with pppGn(n=2)-shRNA-luc
corresponding to the luciferase gene, and then transfected
with pGL3-control (Fireﬂy) and phRG-TK (Renilla)
vectors. We found that pppGn(n=2)-shRNA-luc3 (nt
824–845) and pppGn (n=2)-shRNA-4 (nt 893–914)
greatly inhibited luciferase activity (data not shown).
Recently, Kim et al. (5) demonstrated that siRNAs
synthesized using the T7 RNA polymerase system trigger
the potent induction of IFN-a and IFN-b in a variety of
cells. The mediator of this response was an initiating
50-triphosphate that was required for IFN induction. To
verify the induction of IFN by pppGn(n=2)-shRNA-
luc3, we designed pppGn (n=0–3) in association with the
50-end of shRNA-luc3, which was transcribed by T7 RNA
polymerase (Figure 1A). Luc-3 inhibited luciferase activity
in a dose-dependent manner (Figure 1B). The control
pppGn(n=2)-shRNA-EGFP targeting enhanced green
ﬂuorescent protein did not inhibit luciferase activity
(Figure 1B). Furthermore, the inhibition of luciferase
activity was not due to the residual amount of guanine
associated with the 50-end of the transcript.
We also designed 50-HOGn(n=0–3)-luc-3 with the
50-end of shRNA and tested for IFN induction
(Figure 1A). We assayed the medium of pppGn or
50-HOGn(n=0–3)-shRNA-luc3-transfected HeLa CD4
+
cells for IFN-b using an enzyme-linked immunosorbent
assay (ELISA). IFN assays from pppGn (n=2,3)
associated with the 50-end of shRNA did not induce
IFN in HeLa CD4
+ cells (Figure 2A), whereas a slight
IFN response was induced by pppGn (n=1) associated
with the 50-end of shRNA. pppGn (n=0) associated with
the shRNA 50-end was capable of more potent IFN
induction than pppGn (n=1) associated with the shRNA
50-end. Furthermore, no IFN was induced in HeLa CD4
+
cells by 50-HOGn (n=0–3) (Figure 2A).
To further investigate the pppGn(n=0–3)-shRNA-
luc3-mediated or 50-HOGn(n=0–3)-shRNA-luc3-
mediated IFN response, we monitored cell growth.
pppGn(n=0)-shRNA-luc3-transfected cells showed a
cytopathogenic eﬀect after 3d, but pppGn(n=2,3)-
shRNA-luc3-transfected cells did not (Figure 2B).
A tetrazolium-based MTS assay was next used to examine
the viability of pppGn(n=0–3)-shRNA-luc3-transfected
or 50-HOGn(0–3)-shRNA-luc3-transfected cells. pppGn
(n=2,3) associated with the shRNA 50-end or 50-
HOGn(0–3)-shRNA-luc3 did not induce cellular toxicity
in HeLa CD4
+ cells (Figure 2C), whereas minor cellular
toxicity was induced by pppGn(n=0,1)-shRNA-luc3.
The antiviral activities of IFN have been recently
studied (14), but our data indicate that the presence of a
guanine residue on T7-transcribed RNAs prevents the
activation of IFN. Furthermore, the inhibition of lucifer-
ase activity by pppGn(n=0)-shRNA-luc3 (Figure 2A–C)
might be due, in part, to IFN induction. These results
suggest that the residual amount of guanine associated
with the 50-end of the transcript is proportional to the
reduction of the IFN response.
Inhibition of HIV-1 replication by shRNAs synthesized
using T7RNA polymerase
To conﬁrm the role of residual guanine, we tested the
sequence-speciﬁc inhibition of HIV-1 replication by
shRNAs synthesized using the T7 RNA polymerase. We
applied the shRNA technology to a well-conserved target
in HIV-1: the dimerization initiation site (DIS)
(15,16). The DIS is a stem–loop structure with six self-
complementary nt at the top (Figure 3A), which is located
between the primer binding site and the splice donor site at
the end of a long terminal repeat (LTR) (17). It is involved
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Figure 1. RNAi-mediated silencing of luciferase activity. (A) The
shRNA-luc synthesized in these studies. We designed pppGn (n=0–3)
associated with the 50-end of the shRNA that was transcribed by T7
RNA polymerase. We also designed 50-HOGn (n=0–3) with the 50-end
of the shRNA (removal of triphosphate by CIP). (B) The anti-luciferase
activity of pppGn (n=0–3) associated with the 50-end of shRNA-luc3
in HeLaCD4
+ cells. Fireﬂy and Renilla luciferase activities were
measured consecutively using dual-luciferase assays (Promega) 48h
after transfection. The average results of three independent experiments
are presented.
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proviral synthesis (18–22). There are two major motifs in
HIV-1: GUGCAC in subtypes A and C, and GCGCGC in
subtypes B and D (23,24). The subtype A motif has been
shown to be a good siRNA target in an in vitro cell-free
system where HIV-1 genome dimerization was successfully
inhibited by a 9-mer DIS-targeting siRNA, while the
corresponding DNA oligonucleotide did not aﬀect dimer-
ization (25,26). These studies also showed that sense
oligonucleotides function as competitive inhibitors of this
self-complimentary target.
pppGn(n=2)-shRNA-DIS (shRNA-DIS-1-8) targeted
against the 35-nt stem-loop (nt 248–277) or the 9-nt loop
of the DIS (nt 255–263) were tested for their ability to
inhibit HIV-1 replication (Figure 3B). The eﬀect of
shRNA-DIS-1-8 on HIV-1 (pNL4-3-luc) (27) replication
was measured in a transient assay following its
co-transfection with pNL4-3-luc into HeLa CD4
+ cells.
At 48h post-transfection, luciferase activity was measured
with the dual-luciferase reporter (DLR
TM) assay system.
The luciferase activity of the cell lysate was measured
as an indirect marker of viral replication. Although
shRNA-DIS-3, shRNA-DIS-7 and shRNA-DIS-8 had
strong inhibitory eﬀects compared with shRNA-DIS-1
and shRNA-DIS-2, their anti-HIV-1 activities were lower
than those of shRNA-DIS-4, shRNA-DIS-5 and shRNA-
DIS-6 (Figure 3C). The internal control, pppGn(n=2)-
shRNA-LacZ targeting LacZ protein, did not inhibit
luciferase activity.
Sequence-specific inhibition ofHIV-1 replication by
T7transcribed shRNA-DIS-6
To further investigate the speciﬁc eﬀect of shRNA-DIS6
on the DIS sequence, we examined shRNA-DIS-6 and the
internal control shRNA-LacZ against infection by HIV-
1NL4-3 (Figure 4A). The shRNA-DIS eﬀect was conﬁrmed
as speciﬁc to the DIS gene, because no obvious eﬀects
were observed following the HIV-1NL4-3 challenge.
We next carried out an IFN-b ELISA assay of the
medium of pppGn(n=2)-shRNA-DIS6-transfected,
HOGn(n=0)-shRNA-DIS6-transfected, and ppp
Gn(n=2)-shRNA-LacZ-transfected HeLa CD4
+ cells,
and found no IFN induction (Figure 4B). By contrast,
pppGn (n=0) associated with the shRNA 50-end induced
IFN. Kim et al. (5) reported that the pppGGG-dsRNA
(such as small interfering RNA), when generated by
in vitro transcription, induced IFN. We examined the
inﬂuence of pppGGG associated with short dsRNA
[pppGn(n=2)-siRNA-DIS6] on IFN inducing activity.
When HeLa CD4
+ cells were transfected with
pppGn(n=2)-siRNA-DIS6, we observed IFN induction,
but not the pppGn(n=2)-shRNA-DIS6 (Figure 4B). Our
result on the induce of IFN by pppGn(n=2)-siRNA-
DIS6 was in general agreement with their IFN response as
reported by Kim et al. (5). To further clarify the IFN
response of pppGn (n=0,2) in association with the
shRNA 50-end, we examined the activation of IFN-
regulatory factor-3 (IRF-3) in HeLa CD4
+ cells. We
assessed the trigger of IRF-3 phosphorylation by
pppGn(n=0,2)-shRNA-DIS6 and HOGn(n=0)-
shRNA-DIS6 in HeLa CD4
+ cells by constructing a
luciferase reporter gene-expression vector (pIRF-3/Luc
reporter) with an IRF-3 binding region (50-GAAACCGA
AACT-30) in the pGL3-basic vector (28). pIRF-3/Luc and
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Figure 2. Lack of IFN induction by T7-transcribed shRNA. (A)
The residual amount of guanine associated with the 50-end of the
transcript is essential to prevent IFN induction. HeLaCD4
+ cells
were transfected with 100nM of pppGn(n=0–3)-shRNA-luc3 or
HOGn(n=0–3)-shRNA-luc3. The induced levels of IFN-b were
determined by an ELISA. The IFN results are the average of two
independent experiments. (B) The cytopathic eﬀect of T7-transcribed
pppGn(n=0–3)-shRNA-luc3. HeLaCD4
+ cells were transfected with
100nM of pppGn(n=0–3)-shRNA-luc3 or HOGn(n=0–3)-shRNA-
luc3 and monitored microscopically 3 days post-transfection.
(C) Cytotoxicity of pppGn(n=0–3)-shRNA-luc3 (100nM) or
HOGn(n=0–3)-shRNA-luc3 (100nM) represents the percentage reduc-
tion of viable cell numbers in HeLaCD4
+ cells. The cytotoxicity assay
was performed with an MTS assay. The toxicity results are
representative of three independent experiments.
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into HeLa CD4
+ cells. IRF-3 activation was monitored
using the DLR
TM assay (Figure 4C). The internal control,
polyI:C and pppGn(n=0)-shRNA-DIS6 simultaneously
induced phosphorylation of IRF-3 and luciferase
gene expression in HeLa CD4
+ cells. By contrast,
pppGn(n=2)-shRNA-DIS6 and HOGn(n=0)-shRNA-
DIS6 did not mediate either IRF-3 phosphorylation
or luciferase gene expression in these cells (Figure 4C).
To further clarify the RIG-I-mediated IFN response to
pppGn(n=0,2)-shRNA, we used RNAi to speciﬁcally
target RIG-I in HeLa CD4
+ cells. After 2 days, cells
were transfected with shRNAs [pppGn (n=0,2) or
HOGn(n=0)-shRNA-DIS6] using DMRIE-C, and the
IFN ELISA assay were carried out. However, pppGn
(n=0,2)-shRNA-DIS6 and HOGn(n=0)-shRNA-DIS6
strongly inhibited INF-b production (Figure 4D). These
data indicate that pppGn(n=0)-shRNA induced an
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Figure 3. Inhibition of HIV-1 replication by shRNAs synthesized using T7 RNA polymerase. (A) Schematic of the 9.2-kb HIV genome. The 50-LTRs
and 30-LTRs and all eight open-reading frames are indicated. The untranslated leader RNA consists of several regulatory domains. (B) shRNAs
or siRNA targeted against the DIS of HIV-I RNA (nt 248–277). (C) The eﬀect of shRNA-DIS1-8 on HIV-1 (pNL4-3-luc) replication was measured
in a transient assay following its co-transfection with pNL4-3-luc into HeLa CD4
+ cells. Fireﬂy and Renilla luciferase activities were measured
consecutively using dual-luciferase assays (Promega) 48h after transfection. The luciferase activity of the cell lysate was measured as an indirect
marker of viral replication. The average results of three independent experiments are presented.
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Figure 4. Sequence-speciﬁc inhibition of HIV-1 replication by T7-transcribed shRNA-DIS-6. (A) T7-transcribed pppGn(n=2)-shRNA-DIS6 and
LacZ (control) against challenge infection of HIV-1NL4-3. The average results of three independent experiments are presented. (B) The residual
amount of guanine associated with the 50-end of the transcript is essential to prevent the induction of IFN. HeLaCD4
+ cells were transfected with
100nM of either pppGn(n=0,2)-shRNA-DIS6, HOGn(n=0)-shRNA-DIS6 and pppGn(n=2)-shRNA-LacZ (control) or pppGn(n=2)-siRNA-
DIS6 (control). The induced levels of IFN-b was determined by an ELISA. ND, not detectable. The IFN results are the average of two independent
experiments. (C) Activation of IRF-3 by T7-transcribed shRNA. HeLaCD4
+ cells transfected with pIRF-3/Luc plasmid and Renilla luciferase
control plasmids were either pppGn(n=0,2)-shRNA-DIS6 and HOGn(n=0)-shRNA-DIS6. After 12h, the cell lysates were prepared and assayed
for dual luciferase activity. The average results of three independent experiments are presented. (D) RIG-I siRNA inhibited the IFN-b response by
pppGn(n=0,2)-shRNA-DIS6 or HOGn(n=0)-shRNA-DIS6. HeLaCD4
+ cells were transfected with siRNA targeting RIG-I. After 2d,
HeLaCD4
+ cells were transfected with 100nM of either pppGn(n=0,2)-shRNA-DIS6 or HOGn(n=0)-shRNA-DIS6. The induced levels of
IFN-b were determined by an ELISA. N.D., not detectable. The IFN results are the average of three independent experiments. (E) Cytotoxic eﬀect of
T7-transcribed pppGn(n=2)-shRNA-DIS6 or pppGn(n=2)-shRNA-LacZ. HeLaCD4
+ cells were transfected with pppGn(n=2)-shRNA-DIS6 or
pppGn(n=2)-shRNA-LacZ (control) and monitored microscopically 3 days post-transfection. (F) The cytotoxicity of pppGn(n=0,2)-shRNA-DIS-6
or HOGn(n=2)-shRNA-DIS6 represented as the percentage reduction of viable HeLaCD4
+ cells. A cytotoxicity assay was performed along with
an MTS assay. The toxicity results are representative of the three independent experiments.
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shRNA arrested INF-inducing activity through TLR-3
and RIG-I.
We next monitored cell growth. The pppGn(n=0)-
shRNA-DIS6-transfected cells showed cytopathogenic
eﬀects after 3days, but the pppGn(n=2)-shRNA-DIS6-
transfected cells did not (Figure 4E). Finally, we used the
MTS assay to examine the viability of pppGn(n=0,2)-
shRNA-DIS-6-transfected HeLa CD4
+ cells. HOGn
(n=2)-shRNA-DIS-6 and pppGn(n=2)-shRNA-DIS-6
or LacZ did not induce cellular toxicity (Figure 4E),
whereas control polyI:C and pppGn(n=0)-shRNA-DIS-
6 did (Figure 4F). Together, these data indicate that the
residual guanine associated with the 50-end and the
hairpin-loop structures of the transcript is proportional
to the reduction of the IFN response.
DISCUSSION
The present study demonstrates that the previously
proposed scheme of triphosphate-dependent siRNA
recognition (5) is, in fact, reversed; although T7-
transcribed-siRNA induced a vigorous type I IFN
response, 50OH-siRNA did not.
Our studies raise the question of how the residual
guanine that is associated with the 50-end of the transcript
contributes to reducing the IFN response. To investigate
the RNAi-mediated silencing of luciferase activity, we
synthesized shRNA-luc, including the 50-pppGn (n=0–3)
sequence, because eﬃcient T7 RNA polymerase initiation
requires the ﬁrst and second non-transcribed space of each
RNA to be a guanine. The pppGn (n=2,3) associated
with the 50-end of shRNA does not induce IFN in HeLa
CD4
+ cells (Figure 2A), whereas the IFN response was
weakly initiated by the pppGn (n=1) associated with the
50-end of the shRNA. The pppGn (n=0) associated with
the 50-end of the shRNA more potently induced IFN than
the pppGn (n=1) associated with the 50-end of the
shRNA. Furthermore, 50-HOGn (n=0–3) did not induce
IFN in HeLa CD4
+ cells. Our results suggest that the
residual amount of guanine associated with the 50-end of
the transcript is proportional to the reduction of the IFN
response. In another study, T7-transcribed siRNAs
triggered a potent induction of IFN-a and IFN-b in a
variety of cells, and the mediator of this response was an
initiating 50-triphosphate that was required for IFN
induction (5). More recently, two groups reported that
type I IFN is induced by the activation of RIG-I by
50-triphosphate RNA (6,7). It will be important to
re-examine these data in light of the possibility that
these RNAs contain triphosphates, which complicates the
interpretation. Our data indicate that 50-triphosphates are
responsible for inducing IFN activity, whereas the residual
amount of guanine associated with the 50-end of the
transcript arrests the IFN response. To reconﬁrm the role
of the residual amount of guanine associated with the
50-end of the shRNA, we tested the sequence-speciﬁc
inhibition of HIV-1 replication by shRNAs synthesized
using T7 RNA polymerase. The HIV genome is a homo-
dimer of two sense RNA single strands. We applied the
shRNA technology to a well-conserved target in HIV-1,
the DIS (15,16). The pppGn(n=2)-shRNA-DIS6, as the
target of the DIS gene, was a more potent inhibitor than
the other types of shRNA-DIS. The synthesized
pppGn(n=2)-shRNA-DIS6 did not induce the activation
of IFN (Figure 4B), but not the pppGn(n=0)-shRNA-
DIS6 and pppGn(n=2)-siRNA-DIS6. Furthermore,
the activation of IRF-3 did not induce with the
pppGn(n=2)-shRNA-DIS6 and HOGn(n=0)-shRNA-
DIS6, but not the pppGn(n=0)-shRNA-DIS6
(Figure 4C). However, RIG-I-siRNA transfected cells
which did not stimulation of IFN by both pppGn (n=0)
or pppGn(n=2)-shRNA-DIS6 (Figure 4D). Recently, it
was demonstrated that the pppGGG associated with short
double-stranded RNA (dsRNA; pppGGG-dsRNA) is
recognized by RIG-I but not TLR-3 (5,6). In contrast,
the pppGn(n=2)-shRNA-DIS6 also included pppGGG
on the 50-end of the shRNA, but did not recognize TLR-3
and RIG-I (Figure 4B–D). Furthermore, pppGn(n=2)-
shRNA-DIS6 presented a hairpin-loop structure together
with the 50-pppGGG, but not the presence on pppGGG-
dsRNA. Hence, the pppGGG dsRNA was capable of
inducing IFN (5,6), but the pppGn(n=2)-shRNA-DIS6
with the guanine associated with the 50-end and the
hairpin-loop structures precluded the IFN response. One
study suggested that synthetic short dsRNA with blunt
ends is recognized by RIG-I, and that 2-nt overhangs at
the 30-end block this recognition (7). Taken together, these
data indicate that the mechanism of inducing IFN by
dsRNA with 50-pppGGG can diﬀerentiate between
dsRNAs with or without the guanine associated with the
50-end and hairpin-loop structures. These results demon-
strated an association with sequence-speciﬁc inhibition via
the RNAi mechanism.
In conclusion, shRNAs transcribed by T7 RNA
polymerase activate cells of the immune system cells and
induce IFN production. However, the presence of a
triphosphate on in vitro-transcribed RNAs can induce
activation of the immune system (5). The pppGn (n=2–3)
associated with the 50-end of the shRNA from T7 RNA
polymerase did not induce detectable IFN, whereas
pppGn (n=0,1) associated with the 50-end of the
shRNA did induce IFN. Importantly, the residual
amount of guanine associated with the 50-end and the
hairpin-loop structures of the transcript was proportional
to the reduction of the IFN response. The improved
method of T7 RNA polymerase-mediated shRNA synth-
esis did not require RNase treatment to remove the
initiating 50-nt and triphosphates of the transcripts.
Our identiﬁcation of a putative immunostimulatory
motif with shRNAs provides a basis for the rational
design of synthetic shRNAs that avoid inducing an
immune response. This ﬁnding will help to reduce the
potential for oﬀ-target gene eﬀects.
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